Patient Information
The clinical data presented involves a cohort of 48 patients diagnosed with relapsed or refractory (R/R) acute myeloid leukemia (AML). These patients were specifically selected based on the presence of high-risk molecular features, specifically rearrangements in the lysine methyltransferase 2A (KMT2A) gene or mutations in the nucleophosmin 1 (NPM1) gene. These genetic alterations are known to render the leukemia dependent on the menin-KMT2A interaction for the maintenance of an undifferentiated, proliferative state. The patients in this study had previously failed standard-of-care therapies, including intensive chemotherapy and/or targeted agents, leading to their enrollment in clinical trials for revumenib, a potent and selective menin inhibitor.
